Transdermal agomelatine microemulsion gel: pyramidal screening, statistical optimization and in vivo bioavailability
Agomelatine is a new antidepressant having very low oral drug bioavailability less than 5% due to being liable to extensive hepatic 1st pass effect. This study aimed to deliver agomelatine by transdermal route through formulation and optimization of microemulsion gel. Pyramidal screening was perform...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2017-01-01
|
Series: | Drug Delivery |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/10717544.2017.1365392 |
id |
doaj-bcf1040311984d2aa9ddaccdb734ccee |
---|---|
record_format |
Article |
spelling |
doaj-bcf1040311984d2aa9ddaccdb734ccee2020-11-25T01:28:20ZengTaylor & Francis GroupDrug Delivery1071-75441521-04642017-01-012411159116910.1080/10717544.2017.13653921365392Transdermal agomelatine microemulsion gel: pyramidal screening, statistical optimization and in vivo bioavailabilityMayada Said0Ibrahim Elsayed1Ahmed A. Aboelwafa2Ahmed H. Elshafeey3Faculty of Pharmacy, Cairo UniversityFaculty of Pharmacy, Cairo UniversityFaculty of Pharmacy, Cairo UniversityFaculty of Pharmacy, Cairo UniversityAgomelatine is a new antidepressant having very low oral drug bioavailability less than 5% due to being liable to extensive hepatic 1st pass effect. This study aimed to deliver agomelatine by transdermal route through formulation and optimization of microemulsion gel. Pyramidal screening was performed to select the most suitable ingredients combinations and then, the design expert software was utilized to optimize the microemulsion formulations. The independent variables of the employed mixture design were the percentages of capryol 90 as an oily phase (X1), Cremophor RH40 and Transcutol HP in a ratio of (1:2) as surfactant/cosurfactant mixture ‘Smix’ (X2) and water (X3). The dependent variables were globule size, optical clarity, cumulative amount permeated after 1 and 24 h, respectively (Q1 and Q24) and enhancement ratio (ER). The optimized formula was composed of 5% oil, 45% Smix and 50% water. The optimized microemulsion formula was converted into carbopol-based gel to improve its retention on the skin. It enhanced the drug permeation through rat skin with an enhancement ratio of 37.30 when compared to the drug hydrogel. The optimum ME gel formula was found to have significantly higher Cmax, AUC 0–24 h and AUC0–∞ than that of the reference agomelatine hydrogel and oral solution. This could reveal the prosperity of the optimized microemulsion gel formula to augment the transdermal bioavailability of agomelatine.http://dx.doi.org/10.1080/10717544.2017.1365392microemulsiontransdermald-optimal mixture designoptimizationagomelatine |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Mayada Said Ibrahim Elsayed Ahmed A. Aboelwafa Ahmed H. Elshafeey |
spellingShingle |
Mayada Said Ibrahim Elsayed Ahmed A. Aboelwafa Ahmed H. Elshafeey Transdermal agomelatine microemulsion gel: pyramidal screening, statistical optimization and in vivo bioavailability Drug Delivery microemulsion transdermal d-optimal mixture design optimization agomelatine |
author_facet |
Mayada Said Ibrahim Elsayed Ahmed A. Aboelwafa Ahmed H. Elshafeey |
author_sort |
Mayada Said |
title |
Transdermal agomelatine microemulsion gel: pyramidal screening, statistical optimization and in vivo bioavailability |
title_short |
Transdermal agomelatine microemulsion gel: pyramidal screening, statistical optimization and in vivo bioavailability |
title_full |
Transdermal agomelatine microemulsion gel: pyramidal screening, statistical optimization and in vivo bioavailability |
title_fullStr |
Transdermal agomelatine microemulsion gel: pyramidal screening, statistical optimization and in vivo bioavailability |
title_full_unstemmed |
Transdermal agomelatine microemulsion gel: pyramidal screening, statistical optimization and in vivo bioavailability |
title_sort |
transdermal agomelatine microemulsion gel: pyramidal screening, statistical optimization and in vivo bioavailability |
publisher |
Taylor & Francis Group |
series |
Drug Delivery |
issn |
1071-7544 1521-0464 |
publishDate |
2017-01-01 |
description |
Agomelatine is a new antidepressant having very low oral drug bioavailability less than 5% due to being liable to extensive hepatic 1st pass effect. This study aimed to deliver agomelatine by transdermal route through formulation and optimization of microemulsion gel. Pyramidal screening was performed to select the most suitable ingredients combinations and then, the design expert software was utilized to optimize the microemulsion formulations. The independent variables of the employed mixture design were the percentages of capryol 90 as an oily phase (X1), Cremophor RH40 and Transcutol HP in a ratio of (1:2) as surfactant/cosurfactant mixture ‘Smix’ (X2) and water (X3). The dependent variables were globule size, optical clarity, cumulative amount permeated after 1 and 24 h, respectively (Q1 and Q24) and enhancement ratio (ER). The optimized formula was composed of 5% oil, 45% Smix and 50% water. The optimized microemulsion formula was converted into carbopol-based gel to improve its retention on the skin. It enhanced the drug permeation through rat skin with an enhancement ratio of 37.30 when compared to the drug hydrogel. The optimum ME gel formula was found to have significantly higher Cmax, AUC 0–24 h and AUC0–∞ than that of the reference agomelatine hydrogel and oral solution. This could reveal the prosperity of the optimized microemulsion gel formula to augment the transdermal bioavailability of agomelatine. |
topic |
microemulsion transdermal d-optimal mixture design optimization agomelatine |
url |
http://dx.doi.org/10.1080/10717544.2017.1365392 |
work_keys_str_mv |
AT mayadasaid transdermalagomelatinemicroemulsiongelpyramidalscreeningstatisticaloptimizationandinvivobioavailability AT ibrahimelsayed transdermalagomelatinemicroemulsiongelpyramidalscreeningstatisticaloptimizationandinvivobioavailability AT ahmedaaboelwafa transdermalagomelatinemicroemulsiongelpyramidalscreeningstatisticaloptimizationandinvivobioavailability AT ahmedhelshafeey transdermalagomelatinemicroemulsiongelpyramidalscreeningstatisticaloptimizationandinvivobioavailability |
_version_ |
1725102274332590080 |